(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of 84.76% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Lenz Therapeutics's revenue in 2026 is $20,989,000.On average, 9 Wall Street analysts forecast LENZ's revenue for 2026 to be $607,334,612, with the lowest LENZ revenue forecast at $338,000,367, and the highest LENZ revenue forecast at $817,973,431. On average, 9 Wall Street analysts forecast LENZ's revenue for 2027 to be $2,020,539,858, with the lowest LENZ revenue forecast at $725,164,424, and the highest LENZ revenue forecast at $3,292,211,370.
In 2028, LENZ is forecast to generate $4,312,169,807 in revenue, with the lowest revenue forecast at $1,733,020,065 and the highest revenue forecast at $8,065,917,857.